The firm shows a Beta (market volatility) of 0.1162, which means not very significant fluctuations relative to the market. Let's try to break down what Dermata's beta means in this case. As returns on the market increase, Dermata Therapeutics returns are expected to increase less than the market. However, during the bear market, the loss on holding Dermata Therapeutics will be expected to be smaller as well. Even though it is essential to pay attention to
Dermata Therapeutics historical returns, it is always good to be careful when utilizing equity current trending patterns. Our philosophy towards predicting any stock's
future performance is to check both, its past performance charts as well as the business as a whole, including all available
technical indicators. Dermata Therapeutics exposes twenty-eight different technical indicators, which can help you to evaluate its performance.
Dermata Therapeutics has an expected return of -0.67%. Please be advised to confirm Dermata Therapeutics
semi variance,
rate of daily change, and the
relationship between the
value at risk and
kurtosis to decide if
Dermata Therapeutics performance from the past will be repeated at some point in the near future.
Volatility is a rate at which the price of Dermata Therapeutics or any other equity instrument increases or decreases for a given set of returns. It is measured by calculating the standard deviation of the annualized returns over a given period of time and shows the range to which the price of Dermata Therapeutics may increase or decrease. In other words, similar to Dermata's
beta indicator, it measures the risk of Dermata Therapeutics and helps estimate the fluctuations that may happen in a short period of time. So if prices of Dermata Therapeutics fluctuate rapidly in a short time span, it is termed to have high volatility, and if it swings slowly in a more extended period, it is understood to have low volatility. Please read more on our
technical analysis page.
Watch out for price decline
Please consider monitoring Dermata Therapeutics on a daily basis if you are holding a position in it. Dermata Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Dermata Therapeutics stock to be traded above the $1 level to remain listed. If Dermata Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How does Dermata utilize its cash?
At present, Dermata Therapeutics'
Change In Cash is projected to increase significantly based on the last few years of reporting. . To perform a cash flow analysis of Dermata Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Dermata Therapeutics is receiving and how much cash it distributes out in a given period. The Dermata Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Dermata Therapeutics Gross Profit
Dermata Therapeutics Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Dermata Therapeutics previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Dermata Therapeutics Gross Profit growth over the last 10 years. Please check Dermata Therapeutics'
gross profit and other
fundamental indicators for more details.
Dermata Therapeutics Volatility Drivers
Dermata Therapeutics unsystematic risk is unique to Dermata Therapeutics and usually not directly affected by the market or economic environment. An example of unsystematic risk is the possibility of poor earnings or a layoff due to coronavirus. One may mitigate nonsystematic risk by buying different securities in the same industry or by buying in different sectors. For example, if you have a position in Dermata Therapeutics you can also buy
Phio Pharmaceuticals Corp. You can also mitigate this risk by investing in the health care sector as well as in companies having nothing to do with it. This type of risk is also called diversifiable risk and can be understood from analyzing Dermata Therapeutics important indicators over time. Here we run a correlation analysis between relevant fundamental ratios over at least ten year period to find a relationship in the way they react to changes in Dermata Therapeutics income statement and balance sheet. Here are more
details about Dermata volatility.
Click cells to compare fundamentals
Breaking it down
The big decline in price over the last few months for Dermata Therapeutics could raise concerns from investors as the firm it trading at a share price of
2.81 on
350,800 in volume. The company directors and management failed to add value to investors and positioning the firm supply of money to exploit market volatility in
October. However, diversifying your holdings with Dermata Therapeutics or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 7.72. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Dermata Therapeutics partners.
Another 3 percent rise for Dermata Therapeutics
Skewness just dropped to -1.43, may suggest upcoming price decrease.
As of the 25th of November, Dermata Therapeutics shows the
mean deviation of 4.49, and Coefficient Of Variation of
(909.73). Dermata Therapeutics
technical analysis allows you to utilize
historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of
historical prices and volume momentum, or the prices will eventually revert. We have collected data for nineteen
technical drivers for Dermata Therapeutics, which can be compared to its rivals. Please confirm
Dermata Therapeutics value at risk, and the
relationship between the
jensen alpha and
semi variance to decide if Dermata Therapeutics is priced favorably, providing market reflects its regular price of 2.81 per share. Please also check Dermata Therapeutics
total risk alpha, which is currently at
(0.88) to verify the company can sustain itself at a future point.
Our Bottom Line On Dermata Therapeutics
Whereas some other entities within the biotechnology industry are still a little expensive, even after the recent corrections, Dermata Therapeutics may offer a potential longer-term growth to investors. To sum up, as of the 25th of November 2021, we believe that at this point, Dermata Therapeutics is
undervalued with
above average odds of distress within the next 2 years. However, our primary recommendation on the company is
Strong Sell.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Dermata Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com